NCT05645757View on ClinicalTrials.gov

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

November 3, 2023

Study Completion Date

November 3, 2023

Conditions
Bacterial Infection
Interventions
DRUG

Ertapenem

A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics

OTHER

Placebo

Placebo

DRUG

WCK 6777

A combination of ertapenem (ERT) and zidebactam (ZID)

DRUG

Zidebactam

A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class

Trial Locations (1)

66212

Altasciences Inc - Kansas City, Overland Park

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH